Levomethamphetamine

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Vanished user 0x8cSXE0x6 (talk | contribs) at 21:11, 28 August 2014 (Categories/templates.). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Levomethamphetamine
Clinical data
Routes of
administration
Medical: Inhalation (nasal)
Recreational: Oral, Intravenous, Insufflation, Inhalation, Suppository
Legal status
Legal status
Pharmacokinetic data
MetabolismHepatic
ExcretionRenal
Identifiers
  • (R)-N-methyl-1-phenyl-propan-2-amine
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
ECHA InfoCard100.046.974 Edit this at Wikidata
Chemical and physical data
FormulaC10H15N
Molar mass149.2 g·mol−1
3D model (JSmol)
  • N([C@@H](Cc1ccccc1)C)C
  • InChI=1S/C10H15N/c1-9(11-2)8-10-6-4-3-5-7-10/h3-7,9,11H,8H2,1-2H3/t9-/m1/s1 checkY
  • Key:MYWUZJCMWCOHBA-SECBINFHSA-N checkY
  (verify)

Levomethamphetamine (other names include l-methamphetamine, levodesoxyephedrine, l-desoxyephedrine, levmetamfetamine (INN and USAN), is the levorotary (R-enantiomer) form of methamphetamine. Levomethamphetamine is a sympathomimetic vasoconstrictor which is the active ingredient used in some over-the-counter nasal decongestants including the US formulation of Vicks Vapor Inhaler, but not the Canadian or Indian formulations, which contain only menthol and camphor.

Chemistry

Levomethamphetamine affects the central nervous system, although its effects are weaker and somewhat shorter than those of dextromethamphetamine, so it is not thought to possess the same addiction potential as that of racemic methamphetamine or dextromethamphetamine.[1][2][3] Among its few physiological effects are the vasoconstriction that makes it useful for nasal decongestion.[4] The elimination half-life of levomethamphetamine is between 13.3 and 15 hours, whereas dextromethamphetamine has a half-life of about 10.5 hours.[5]

Side effects

When used as a nasal decongestant, levomethamphetamine has potential side effects resembling those of other sympathomimetic drugs used for the same purpose; these effects include hypertension (elevated blood pressure), tachycardia (rapid heart rate), nausea, stomach cramps, dizziness, headache, and tremors.[citation needed]

Abuse potential

In a study of psychoactive effects of levomethamphetamine, the intravenous administration of 0.5 mg/kg (but not 0.25 mg/kg) in experienced methamphetamine users produced scores of "drug liking" similar to racemic methamphetamine, but the effects were shorter lived. The study did not test the oral administration of levomethamphetamine. Currently there are no studies demonstrating "drug liking" scores of oral levomethamphetamine that are similar to racemic methamphetamine or dextromethamphetamine in either naive or experienced methamphetamine users.[2]

References

  1. ^ Melega, WP; Cho, AK; Schmitz, D; Kuczenski, R; Segal, DS (February 1999). "l-methamphetamine pharmacokinetics and pharmacodynamics for assessment of in vivo deprenyl-derived l-methamphetamine". The Journal of pharmacology and experimental therapeutics. 288 (2): 752–8. PMID 9918585.
  2. ^ a b Mendelson, J (October 2006). "Human pharmacology of the methamphetamine stereoisomers". Clinical pharmacology and therapeutics. 80 (4): 403–20. doi:10.1016/j.clpt.2006.06.013. PMID 17015058. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  3. ^ Kuczenski, R; Segal, DS; Cho, AK; Melega, W (February 1995). "Hippocampus norepinephrine, caudate dopamine and serotonin, and behavioral responses to the stereoisomers of amphetamine and methamphetamine". The Journal of neuroscience : the official journal of the Society for Neuroscience. 15 (2): 1308–17. PMID 7869099.
  4. ^ Nonprescription Products to Avoid With Hypertension by W. Steven Pray, PhD, DPh, Bernhardt Professor, Nonprescription Products and Devices, College of Pharmacy, Southwestern Oklahoma State University, Weatherford, Oklahoma US Pharm. 2010;35(2):12-15. Posted 19 February 2010. Accessed via internet 26 May 2010. This new article incorporates the information formerly drawn from the article cited at the corresponding point in a previous version of this page, which article's former URL now forms a dead link.
  5. ^ Mendelson J, Uemura N, Harris D; et al. (October 2006). "Human pharmacology of the methamphetamine stereoisomers". Clin. Pharmacol. Ther. 80 (4): 403–20. doi:10.1016/j.clpt.2006.06.013. PMID 17015058. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)